直接致信遗传性癌症高危亲属——瑞典癌症遗传门诊医疗辅助与家庭介导风险披露多中心随机对照试验研究方案(DIRECT研究)
本研究为在瑞典癌症遗传门诊开展的两臂随机对照试验,招募携带癌症易感基因致病性变异或基于临床和系谱标准符合家族性乳腺癌和结直肠癌的先证者。两组均接受标准照护,干预组额外提供直接致信高危亲属的选项,主要结局为亲属在12个月内联系遗传门诊的比例。
要点
- 标准照护鼓励先证者向亲属传递风险信息,家庭介导披露下仅约三分之一高危亲属联系医疗接受遗传咨询。
- 部分研究显示医疗辅助披露补充家庭介导披露可使高危亲属接受遗传咨询的比例几乎翻倍。
- 本试验主要结局为亲属在拿到检测结果后12个月内联系瑞典癌症遗传门诊的比例。
核心结论
- 研究方案描述了一项评估医疗辅助风险披露的随机对照试验,即向先证者提供向高危亲属直接致信选项,结果应为癌症遗传门诊未来风险披露实践的发展提供信息。
研究设计与样本
- 两臂随机对照试验,从瑞典门诊癌症遗传门诊招募先证者。
- 招募对象为携带癌症易感基因(BRCA1、BRCA2、PALB2、MLH1、MSH2、MSH6、PMS2)致病性变异的先证者,或基于临床和系谱标准符合家族性乳腺癌和结直肠癌的先证者。
主要发现
- 两组均接受标准照护,即鼓励和支持先证者向亲属传递信息。
- 干预组额外向先证者提供向高危亲属发送直接信件的机会。
- 主要结局指标为先证者收到检测结果后12个月内联系瑞典癌症遗传门诊的高危亲属比例。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The results of germline genetic testing for hereditary cancer are of importance not only to the patients under investigation but also to their genetic at-risk relatives. Standard care is to encourage the proband (first family member under investigation) to pass on this risk information to the relatives. Previous research suggests that with family-mediated disclosure, only about a third of at-risk relatives contact health care to receive genetic counselling. In some studies, complementing family-mediated risk disclosure with healthcare-assisted risk disclosure almost doubles the uptake of genetic counselling in at-risk relatives. In this study, we evaluate healthcare-assisted direct letters to relatives at risk of hereditary cancer syndromes in a randomized controlled trial. METHODS: Probands are recruited from Swedish outpatient cancer genetics clinics to this two-arm randomized controlled trial. The study recruits probands with either a pathogenic variant in a cancer susceptibility gene (BRCA1, BRCA2, PALB2, MLH1, MSH2, MSH6, PMS2) or probands with familial breast and colorectal cancer based on clinical and pedigree criteria. In both arms, probands receive standard care, i.e., are encouraged and supported to pass on information to relatives. In the intervention arm, the proband is also offered to have direct letters sent to the at-risk relatives. The primary outcome measure is the proportion of at-risk relatives contacting a Swedish cancer genetics clinic within 12 months of the proband receiving the test results. DISCUSSION: This paper describes the protocol of a randomized controlled clinical trial evaluating a healthcare-assisted approach to risk disclosure by offering the probands to send direct letters to their at-risk relatives. The results of this study should be informative in the future development of risk disclosure practices in cancer genetics clinics. TRIAL REGISTRATION: ClinicalTrials.gov. Identifier NCT04197856 (pre-trial registration on December 13, 2019). Also registered at the website "RCC Cancerstudier i Sverige" as study #86719.
引用
- Hawranek C, Ehrencrona H, Öfverholm A, et al. Direct letters to relatives at risk of hereditary cancer-study protocol for a multi-center randomized controlled trial of healthcare-assisted versus family-mediated risk disclosure at Swedish cancer genetics clinics (DIRECT-study). Trials. 2023. PMID: 38105176. doi:10.1186/s13063-023-07829-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。